BioLife Solutions (BLFS) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 07, 2022
Document Information [Line Items]
Entity Central Index Key	0000834365
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-36362
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3076866
Entity Address, Address Line One	3303 Monte Villa Parkway, Suite 310
Entity Address, City or Town	Bothell
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98021
City Area Code	425
Local Phone Number	402-1400
Title of 12(b) Security	BioLife Solutions, Inc. Common Stock
Trading Symbol	BLFS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		42,765,994

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 27,036	$ 69,860
Restricted cash	31	10
Available-for-sale securities, current portion	34,583	0
Accounts receivable, trade, net of allowance for doubtful accounts of $496 and $275 as of September 30, 2022 and December 31, 2021, respectively	32,436	23,217
Inventories	33,747	28,345
Prepaid expenses and other current assets	8,041	4,427
Total current assets	135,874	125,859
Assets held for rent, net	9,357	9,809
Property and equipment, net	21,737	17,657
Operating lease right-of-use assets, net	15,832	18,705
Financing lease right-of-use assets, net	310	440
Long-term deposits and other assets	256	325
Available-for-sale securities, long-term	490	0
Equity investments	5,069	4,372
Total intangible assets, net	74,013	152,149
Goodwill	224,741	224,741
Total assets	487,679	554,057
Current liabilities:
Accounts payable	13,140	14,945
Accrued expenses and other current liabilities	7,778	7,142
Warranty liability	8,367	9,398
Lease liabilities, operating, current portion	2,769	2,758
Lease liabilities, financing, current portion	156	149
Debt, current portion	2,067	862
Contingent consideration, current portion	2,671	5,127
Total current liabilities	36,948	40,381
Contingent consideration, long-term	3,191	4,900
Lease liabilities, operating, long-term	14,474	16,466
Lease liabilities, financing, long-term	166	291
Debt, long-term	24,207	6,353
Deferred tax liabilities	389	5,487
Other long-term liabilities	55	42
Total liabilities	79,430	73,920
Commitments and contingencies (Note 18)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 42,706,044 and 41,817,503 shares issued and outstanding, respectively, as of September 30, 2022 and December 31, 2021	43	42
Additional paid-in capital	604,060	585,397
Accumulated other comprehensive loss, net of taxes	(1,257)	(282)
Accumulated deficit	(194,597)	(105,020)
Total shareholders’ equity	408,249	480,137
Total liabilities and shareholders’ equity	$ 487,679	$ 554,057

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounts receivable, allowance for doubtful accounts	$ 496	$ 275
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	42,706,044	41,817,503
Common stock, outstanding (in shares)	42,706,044	41,817,503
Series A Preferred Stock [Member]
Preferred stock, shares designated (in shares)	4,250	4,250
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue	$ 40,747	$ 33,800	$ 117,500	$ 81,851
Costs and operating expenses:
General and administrative	11,581	10,081	34,128	22,058
Sales and marketing	5,277	4,065	15,583	9,228
Research and development	3,425	3,219	10,634	8,250
Intangible asset impairment charges	0	0	69,900	0
Intangible asset amortization	2,513	2,525	8,236	5,340
Acquisition costs	1	345	18	1,616
Change in fair value of contingent consideration	2,346	(140)	(3,348)	1,086
Total operating expenses	52,152	44,959	212,800	98,546
Operating loss	(11,405)	(11,159)	(95,300)	(16,695)
Other income:
Change in fair value of investments	697	0	697	0
Interest income (expense), net	10	(194)	(181)	(331)
Other income (expense), net	142	(7)	270	(7)
Change in fair value of warrant liability	0	0	0	(121)
Gain on acquisition of Sexton Biotechnologies, Inc.	0	6,451	0	6,451
Total other income, net	849	6,250	786	5,992
Loss before income tax benefit	(10,556)	(4,909)	(94,514)	(10,703)
Income tax benefit	599	4,988	4,937	17,540
Net (loss) income	(9,957)	79	(89,577)	6,837
Net (loss) income attributable to common shareholders:
Basic	(9,957)	77	(89,577)	6,621
Diluted	$ (9,957)	$ 77	$ (89,577)	$ 6,628
Basic (in dollars per share)	$ (0.23)	$ 0	$ (2.11)	$ 0.18
Diluted (in dollars per share)	$ (0.23)	$ 0	$ (2.11)	$ 0.17
Weighted average shares used to compute (loss) earnings per share attributable to common shareholders:
Basic (in shares)	42,647,967	40,911,801	42,376,392	37,435,224
Diluted (in shares)	42,647,967	43,296,470	42,376,392	39,984,923
Product [Member]
Revenue	$ 33,668	$ 29,201	$ 98,227	$ 70,445
Costs and operating expenses:
Cost of goods and services	21,876	21,672	63,377	43,280
Service Revenue [Member]
Revenue	4,330	2,250	11,117	6,417
Costs and operating expenses:
Cost of goods and services	3,253	1,768	8,810	4,548
Rental Revenue [Member]
Revenue	2,749	2,349	8,156	4,989
Costs and operating expenses:
Cost of goods and services	$ 1,880	$ 1,424	$ 5,462	$ 3,140

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net (loss) income	$ (9,957)	$ 79	$ (89,577)	$ 6,837
Other comprehensive loss:
Foreign currency translation adjustment, net of tax	(321)	(166)	(900)	(163)
Unrealized loss on available-for-sale securities, net of tax	(36)	0	(75)	0
Comprehensive (loss) income	$ (10,314)	$ (87)	$ (90,552)	$ 6,674

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	GCI Acquisition [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	GCI Acquisition [Member] Common Stock [Member]	GCI Acquisition [Member] Additional Paid-in Capital [Member]	GCI Acquisition [Member] AOCI Attributable to Parent [Member]	GCI Acquisition [Member] Retained Earnings [Member]	GCI Acquisition [Member]	Sexton Acquisition [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Sexton Acquisition [Member] Common Stock [Member]	Sexton Acquisition [Member] Additional Paid-in Capital [Member]	Sexton Acquisition [Member] AOCI Attributable to Parent [Member]	Sexton Acquisition [Member] Retained Earnings [Member]	Sexton Acquisition [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020													0	33,039,146
Balance at Dec. 31, 2020													$ 0	$ 33	$ 302,598	$ 0	$ (97,385)	$ 205,246
Fees incurred for registration filings													0	0	(188)	0	0	(188)
Stock-based compensation													$ 0	$ 0	8,891	0	0	8,891
Stock option exercises (in shares)													0	632,665
Stock option exercises													$ 0	$ 1	1,016	0	0	1,017
Stock issued – on vested RSAs (in shares)													0	535,378
Stock issued – on vested RSAs													$ 0	$ 0	0	0	0	0
Foreign currency translation													0	0	0	(163)	0	(163)
Net (loss) income													$ 0	$ 0	0	0	6,837	6,837
Stock issued in acquisitions (in shares)	0	6,636,470					0	530,502
Stock issued in acquisitions	$ 0	$ 7	$ 232,734	$ 0	$ 0	$ 232,741	$ 0	$ 0	$ 31,977	$ 0	$ 0	$ 31,977
Cashless exercises of warrants (in shares)													0	70,030
Cashless exercises of warrants													$ 0	$ 0	2,901	0	0	2,901
Balance (in shares) at Sep. 30, 2021													0	41,444,191
Balance at Sep. 30, 2021													$ 0	$ 41	579,929	(163)	(90,548)	489,259
Balance (in shares) at Jun. 30, 2021													0	40,560,720
Balance at Jun. 30, 2021													$ 0	$ 41	542,864	3	(90,627)	452,281
Fees incurred for registration filings													0	0	(188)	0	0	(188)
Stock-based compensation													$ 0	$ 0	4,868	0	0	4,868
Stock option exercises (in shares)													0	244,906
Stock option exercises													$ 0	$ 0	408	0	0	408
Stock issued – on vested RSAs (in shares)													0	108,063
Stock issued – on vested RSAs													$ 0	$ 0	0	0	0	0
Foreign currency translation													0	0	0	(166)	0	(166)
Net (loss) income													$ 0	$ 0	0	0	79	79
Stock issued in acquisitions (in shares)							0	530,502
Stock issued in acquisitions							$ 0	$ 0	$ 31,977	$ 0	$ 0	$ 31,977
Balance (in shares) at Sep. 30, 2021													0	41,444,191
Balance at Sep. 30, 2021													$ 0	$ 41	579,929	(163)	(90,548)	489,259
Balance (in shares) at Dec. 31, 2021													0	41,817,503
Balance at Dec. 31, 2021													$ 0	$ 42	585,397	(282)	(105,020)	480,137
Fees incurred for registration filings													0	0	(130)	0	0	(130)
Stock-based compensation													$ 0	$ 0	17,671	0	0	17,671
Stock option exercises (in shares)													0	158,075
Stock option exercises													$ 0	$ 0	307	0	0	307
Stock issued – on vested RSAs (in shares)													0	666,336
Stock issued – on vested RSAs													$ 0	$ 1	(1)	0	0	0
Contingent consideration shares issued (in shares)													0	64,130
Contingent consideration shares issued													$ 0	$ 0	816	0	0	816
Foreign currency translation													0	0	0	(900)	0	(900)
Unrealized loss on available-for-sale securities													0	0	0	(75)	0	(75)
Net (loss) income													$ 0	$ 0	0	0	(89,577)	(89,577)
Balance (in shares) at Sep. 30, 2022													0	42,706,044
Balance at Sep. 30, 2022													$ 0	$ 43	604,060	(1,257)	(194,597)	408,249
Balance (in shares) at Jun. 30, 2022													0	42,536,734
Balance at Jun. 30, 2022													$ 0	$ 43	597,810	(900)	(184,640)	412,313
Fees incurred for registration filings													0	0	(55)	0	0	(55)
Stock-based compensation													$ 0	$ 0	6,299	0	0	6,299
Stock option exercises (in shares)													0	3,571
Stock option exercises													$ 0	$ 0	6	0	0	6
Stock issued – on vested RSAs (in shares)													0	165,739
Stock issued – on vested RSAs													$ 0	$ 0	0	0	0	0
Foreign currency translation													0	0	0	(321)	0	(321)
Unrealized loss on available-for-sale securities													0	0	0	(36)	0	(36)
Net (loss) income													$ 0	$ 0	0	0	(9,957)	(9,957)
Balance (in shares) at Sep. 30, 2022													0	42,706,044
Balance at Sep. 30, 2022													$ 0	$ 43	$ 604,060	$ (1,257)	$ (194,597)	$ 408,249

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Shareholders' Equity (Parentheticals) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cashless warrant exercises (in shares)	0	79,100

Unaudited Condensed Consolida_7

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net (loss) income	$ (89,577)	$ 6,837
Adjustments to reconcile net (loss) income to net cash used in operating activities
Intangible asset impairment charges	69,900	0
Stock-based compensation	17,671	8,891
Amortization of intangible assets	8,236	5,340
Depreciation	5,056	3,035
Non-cash lease expense	1,025	1,795
Loss on disposal of property and equipment, net	54	0
(Gain) loss on disposal of assets held for rent, net	369	333
Change in fair value of warrant liability	0	121
Change in fair value of equity investments	(697)	0
Change in fair value of contingent consideration	(3,348)	1,086
Deferred income tax benefit	(4,937)	(17,540)
Gain on acquisition of Sexton Biotechnologies, Inc.	0	(6,451)
Other	302	504
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	(9,438)	(7,140)
Inventories	(5,403)	(1,237)
Prepaid expenses and other assets	(1,356)	1,769
Accounts payable	(3,615)	1,368
Accrued expenses and other current liabilities	444	(2,530)
Warranty liability	(1,031)	0
Net cash used in operating activities	(16,345)	(3,819)
Cash flows from investing activities
Cash acquired in acquisition of Global Cooling, Inc.	0	1,559
Maturities of available-for-sale securities	750
Proceeds from sale of equipment	0	22
Purchases of assets held for rent	(2,269)	(5,412)
Purchases of property and equipment	(5,937)	(6,819)
Investment in available-for-sale securities	(35,767)	0
Net cash used in investing activities	(43,223)	(10,650)
Cash flows from financing activities
Proceeds from line of credit	0	26,450
Payments on line of credit	0	(28,657)
Proceeds from exercise of common stock options	307	1,017
Fees paid related to issuance of common stock	(130)	(145)
Other	(302)	(280)
Net cash provided by (used in) financing activities	16,941	(673)
Net decrease in cash, cash equivalents, and restricted cash	(42,627)	(15,142)
Cash, cash equivalents, and restricted cash – beginning of period	69,870	90,456
Effects of currency translation on cash, cash equivalents, and restricted cash	(176)	(163)
Cash, cash equivalents, and restricted cash – end of period	27,067	75,151
Non-cash investing and financing activities
Purchase of property and equipment not yet paid	1,661	305
Cashless issuance of SciSafe earnout shares	817	0
Equipment acquired under operating leases	243	6,971
Unrealized gains and losses on available-for-sale securities	75	0
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc.	0	264,718
Cashless exercise of warrants reclassified from warrant liability to common stock	0	2,901
Equipment acquired under finance leases	0	440
Cash interest paid	230	0
The 2022 Term Loan [Member]
Cash flows from financing activities
Proceeds from loans	20,000	0
Payments on loans	(1,750)	0
Equipment Loans [Member]
Cash flows from financing activities
Proceeds from loans	0	1,640
Payments on loans	(370)	0
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium	$ (814)	$ (698)

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated cell processing fill machines, closed system cryogenic vials, human platelet lysate (“hPL”) growth media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes hPL media, for cell expansion reducing risk and improving downstream performance inherent with the use of fetal bovine serum and human serum, and CellSeal® cryogenic vials, which are purpose-built rigid containers used as a primary final package for cells used in research and clinical applications. These vials can be filled manually or with high throughput systems and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is comprised of a family of automated thawing devices for frozen biologic material packaged in cryovials and cryobags. These products help to reduce thawing related damage to temperature-sensitive biologic materials by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our cryogenic freezer technology provides for controlled rate freezing and cryogenic storage of biologic materials. Our ultra-low temperature mechanical freezers allow biological materials to be stored at temperatures which range from negative 20℃ 86℃. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the recoverability of the Company’s deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Unaudited Condensed Consolidated Financial Statements included herein have been prepared by BioLife in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10 10 X not 10 December 31, 2021. The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU” acquired on August 8, 2019), November 12, 2019), October 1, 2020), April 1, 2021), May 3, 2021), September 1, 2021). In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheet, Unaudited Condensed Consolidated Statements of Operations, Unaudited Condensed Consolidated Statements of Shareholders’ Equity, and Unaudited Condensed Consolidated Statements of Cash Flows into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one Significant accounting policies The following describes an update to the Company’s accounting policies for investments. For a full discussion of significant accounting policies, including additional information regarding the Company’s accounting policies for investments, refer to the Notes to the Consolidated Financial Statements included within the Company’s Annual Report on Form 10 December 31, 2021. The Company classifies its investment in marketable debt securities as “available-for-sale.” Available-for-sale securities are carried at fair value with unrealized holding gains or losses recorded in other comprehensive income, net of tax. Gains or losses are included in earnings in the period in which they are realized. The cost of securities sold is determined based on the specific identification method. The cost of available-for-sale debt securities is adjusted for premiums and discounts, with the accretion or amortization of such amounts included as a portion of interest. Available-for-sale debt securities with an original maturity date less than one one Liquidity and capital resources On September 30, 2022 December 31, 2021, 2022 3. 11 2022 3. twelve 10 may may not Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” In the nine September 30, 2022 December 31, 2021, 19 not 19 19. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 Concentrations of credit risk and business risk Significant customers are those that represent more than 10% Accounts Receivable Revenue September 30, December 31, Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 2022 2021 Customer A 22 % 21 % * * * * Customer B 10 % 11 % 17 % 19 % 19 % 14 % * less than 10% Revenue from foreign customers is denominated in United States dollars or euros. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Nine Months Ended September 30, September 30, Revenue by customers geographic locations 2022 2021 2022 2021 United States 69 % 82 % 74 % 80 % Europe, Middle East, Africa (EMEA) 20 % 9 % 18 % 10 % Canada 8 % 6 % 5 % 7 % Other 3 % 3 % 3 % 3 % Total revenue 100 % 100 % 100 % 100 % In the three nine September 30, 2022 2021, no 10% As of September 30, 2022 December 31, 2021, . Recent accounting pronouncements In June 2022, No. 2022 03, Fair Value Measurements (Topic 820 820” 2022 03 1 820, 2 3 820. 2022 03 not not December 15, 2023, 2022 03. not In March 2022, No. 2022 02 Financial Instruments-Credit Losses (Topic 326 2022 02 2022 02 326 2022 02 December 15, 2022 2022 02

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. Fair value measurement In accordance with FASB ASC Topic 820, 1 2 2 3 1 820 820 three Level 1 Level 2 1 not Level 3 The fair value of the CBS Contingent Consideration Liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 26.0%, a risk-free rate of approximately 1.74% and revenue volatility of 70%. Significant changes in any of those inputs in isolation would result in a significant change in the fair value measurement of the liability. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2021, September 30, 2022 December 31, 2021 The fair value of the SciSafe Contingent Consideration Liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.20%, asset volatility of 60%, and revenue volatility of 15%. Significant changes in any of those inputs in isolation would result in a significant change in the fair value measurement of the liability. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not September 30, 2022, September 30, 2022 December 31, 2021 three nine September 30, 2022, three nine September 30, 2021, second 2022, first For the warrant liability, the significant Level 3 March 25, 2021. There were no three nine September 30, 2022 not The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 December 31, 2021, three (In thousands) As of September 30, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 22,868 $ - $ - $ 22,868 Available-for-sale securities: U.S. government securities 13,054 - - 13,054 Corporate debt securities - 20,094 - 20,094 Other debt securities - 1,925 - 1,925 Total 35,922 22,019 - 57,941 Liabilities: Contingent consideration - business combinations - - 5,862 5,862 Debt - 26,274 - 26,274 Total $ - $ 26,274 $ 5,862 $ 32,136 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Debt - 7,215 - 7,215 Total $ - $ 7,215 $ 10,027 $ 17,242 There have been no The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance as of December 31, 2021 and 2020 $ 10,027 $ 7,152 Change in fair value recognized in net (loss) income (3,348 ) 1,086 Payment of contingent consideration earned (817 ) - Ending balance $ 5,862 $ 8,238 The following table presents the changes in fair value of warrant liabilities which are measured using Level 3 Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance as of December 31, 2021 and 2020 $ - $ 2,780 Exercised warrants - (2,901 ) Change in fair value recognized in net (loss) income - 121 Ending balance $ - $ -

Note 3 - Investments

Note 3 - Investments	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Investment [Text Block]	3. Available-for-sale securities The Company’s portfolio of available-for-sale marketable securities consists of the following: September 30, 2022 Amortized Gross unrealized Estimated (In thousands) Cost Gains Losses Fair Value Available-for-sale securities, current portion U.S. government securities $ 13,102 $ - $ 48 $ 13,054 Corporate debt securities 20,112 - 18 20,094 Other debt securities 1,444 - 9 1,435 Total short-term 34,658 - 75 34,583 Available-for-sale securities, long-term Other debt securities 490 - - 490 Total marketable securities $ 35,148 $ - $ 75 $ 35,073 Amortized Estimated (In thousands) Cost Fair Value Due in one year or less $ 34,658 $ 34,583 Due after one year through five years 490 490 Total $ 35,148 $ 35,073 There were no December 31, 2021. Equity investments The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. These securities included Series A- 1 2 September 30, 2022 December 31, 2021, September 30, 2022 December 31, 2021.

Note 4 - Inventory

Note 4 - Inventory	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory consists of the following as of September 30, 2022 December 31, 2021: (In thousands) 2022 2021 Raw materials $ 18,241 $ 17,252 Work in progress 5,454 5,015 Finished goods 10,052 6,078 Total $ 33,747 $ 28,345

Note 5 - Leases

Note 5 - Leases	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Lessee, Leases [Text Block]	5. The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases have remaining lease terms of one ten not one five one five Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of September 30, 2022 December 31, 2021: September 30, December 31, (In thousands) 2022 2021 Weighted average discount rate - operating leases 3.8 % 3.8 % Weighted average discount rate - finance leases 6.1 % 6.1 % Weighted average remaining lease term in years - operating leases 7.3 7.8 Weighted average remaining lease term in years - finance leases 2.3 3.0 The components of lease expense for the three nine September 30, 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2022 2021 2022 2021 Operating lease costs $ 909 $ 805 $ 2,745 $ 1,998 Short-term lease costs 534 498 1,627 1,158 Total operating lease costs 1,443 1,303 4,372 3,156 Variable lease costs 250 193 809 477 Total lease costs $ 1,693 $ 1,496 $ 5,181 $ 3,633 Maturities of our lease liabilities as of September 30, 2022 (In thousands) Operating Leases Financing Leases 2022 (3 months remaining) $ 1,014 $ 43 2023 3,158 171 2024 2,882 101 2025 2,428 28 2026 1,997 2 Thereafter 8,278 - Total lease payments 19,757 345 Less: interest (2,514 ) (23 ) Total present value of lease liabilities $ 17,243 $ 322

Note 6 - Assets Held for Rent

Note 6 - Assets Held for Rent	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Assets Held For Rent [Text Block]	6. Assets held for rent Assets held for rent consist of the following as of September 30, 2022 December 31, 2021: (In thousands) 2022 2021 Shippers placed in service $ 7,375 $ 5,645 Fixed assets held for rent 4,686 4,040 Accumulated depreciation (4,571 ) (2,272 ) Net 7,490 7,413 Shippers and related components in production 1,867 2,396 Total $ 9,357 $ 9,809 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $921,000 and $2.7 million in depreciation expense related to assets held for rent during the three nine September 30, 2022, three nine September 30, 2021,

Note 7 - Property and Equipment

Note 7 - Property and Equipment	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Property, Plant, and Equipment and Intangible Assets [Text Block]	7. Property and equipment consist of the following as of September 30, 2022 December 31, 2021: September 30, December 31, (In thousands) 2022 2021 Property and equipment Leasehold improvements $ 5,069 $ 3,840 Furniture and computer equipment 1,874 1,861 Manufacturing and other equipment 19,715 16,675 Construction in-progress 3,767 2,022 Subtotal 30,425 24,398 Less: Accumulated depreciation (8,688 ) (6,741 ) Property and equipment, net $ 21,737 $ 17,657 Depreciation expense for property and equipment was $865,000 and $2.4 million for the three nine September 30, 2022, three nine September 30, 2021,

Note 8 - Goodwill and Intangibl

Note 8 - Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	8. Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not 350. Intangible assets Intangible assets, net consisted of the following as of September 30, 2022 December 31, 2021: (In thousands, except weighted average useful life) September 30, 2022 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 15,984 $ (3,539 ) $ 12,445 9.6 Tradenames 29,635 (4,091 ) 25,544 13.1 Technology - acquired 38,410 (12,063 ) 26,347 5.1 Non-compete agreements 1,986 (856 ) 1,130 2.3 In-process research and development (1) 8,547 - 8,547 N/A Total intangible assets $ 94,562 $ (20,549 ) $ 74,013 9.0 (In thousands, except weighted average useful life) December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development (1) 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8 ( 1 Amortization expense for definite-lived intangible assets was $2.5 million and $8.2 million for the three nine September 30, 2022, three nine September 30, 2021, September 30, 2022, (In thousands) Amortization For the Years Ending December 31, Expense 2022 (3 months remaining) $ 2,494 2023 9,570 2024 8,745 2025 8,398 2026 7,975 Thereafter 28,284 Total $ 65,466 Interim impairment testing In the six June 30, 2022, July 2022, three June 30, 2022 To assess any potential impairment of goodwill, the Company compared the carrying value of its single reporting unit against its market capitalization, noting that the market capitalization exceeded the carrying value. As such, goodwill was not June 30, 2022. The abandonment of the aforementioned in-process research and development project resulted in a $8.0 million non-cash impairment charge during the three June 30, 2022 In order to determine the fair value of our in-process research and development intangible assets not three June 30, 2022 In order to determine the fair value of the acquired technology, customer relationships, tradename, and non-compete definite-lived intangible assets, the Company utilized the excess earnings approach, distributor method, relief from royalty method, and with and without approach, respectively. The key assumptions associated with determining the estimated fair value include (i) the amount and timing of projected future cash flows (including revenue and expenses), (ii) the discount rate selected to measure the risks inherent in the future cash flows, (iii) the assessment of the asset’s life cycle, and (iv) the competitive trends impacting the asset. As a result of the analysis, we recognized non-cash impairment charges of $3.5 million, $1.5 million, $5.9 million, and $4,000 during the period ended June 30, 2022 Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions, estimates and market factors. Estimating the fair value of the Company’s reporting unit, indefinite-lived intangible assets, and definite-lived intangible assets requires us to make assumptions and estimates regarding our future plans, as well as industry, economic, and regulatory conditions. These assumptions and estimates include projected future revenue growth rates, EBITDA margins, terminal growth rates, discount rates, royalty rates and other market factors. If current expectations of future growth rates, margins and cash flows are not June 30, 2022 The Company performed a qualitative impairment assessment as of September 30, 2022. no September 30, 2022.

Note 9 - Accrued Expenses and O

Note 9 - Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	9. Accrued expenses and other current liabilities consist of the following as of September 30, 2022 December 31, 2021: September 30, December 31, (In thousands) 2022 2021 Accrued compensation $ 4,706 $ 4,351 Accrued expenses 1,470 1,656 Deferred revenue, current 429 814 Accrued taxes 1,151 27 Other 22 294 Total accrued expenses and other current liabilities $ 7,778 $ 7,142

Note 10 - Warranty Reserve Liab

Note 10 - Warranty Reserve Liability	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Product Warranty Disclosure [Text Block]	10. The Company reserves estimated exposures on known claims, as well as anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance as of December 31, 2021 and 2020 $ 9,398 $ 212 Warranty reserve acquired in the acquisition of Global Cooling - 3,353 Provision for warranties 1,770 4,446 Settlements of warranty claims (2,801 ) (2,459 ) Ending Balance $ 8,367 $ 5,552

Note 11 - Long-term Debt

Note 11 - Long-term Debt	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Long-Term Debt [Text Block]	11. 2022 3 On September 20, 2022, June 1, 2026. June 30, 2023, $10 $10 June 2024, June 2025. 2022 3 2022 3 $20 Long-term debt consisted of the following as of September 30, 2022 December 31, 2021: September 30, December 31, (In thousands) Maturity Date Interest Rate 2022 2021 2022 term loan 1 (1) 4.0 % $ - $ 1,750 2022 term loan 2 Various 4.0 % 2,896 2,813 2022 term loan 3 Jun-26 6.8 % 20,000 - Insurance premium financing Apr-23 5.0 % 1,635 373 Freezer equipment loan Dec-25 5.7 % 502 612 Manufacturing equipment loans Oct-25 5.7 % 288 355 Freezer installation loan Various 6.3 % 1,143 1,334 Other loans Various Various 8 9 Total debt, excluding unamortized debt issuance costs 26,472 7,246 Less: unamortized debt issuance costs (198 ) (31 ) Total debt 26,274 7,215 Less: current portion (2,067 ) (862 ) Total long-term debt $ 24,207 $ 6,353 ( 1 2022 1 September 2024 December 31, 2021. September 30, 2022, 2022 3 2022 2 2022 3. As of September 30, 2022, five (In thousands) Amount 2022 (3 months remaining) $ 679 2023 1,888 2024 5,544 2025 10,543 2026 5,222 Thereafter 2,596 Total debt, excluding unamortized debt issuance costs 26,472 Less: unamortized debt issuance costs (198 ) Total debt $ 26,274

Note 12 - Warrants

Note 12 - Warrants	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Warrants [Text Block]	12. In March 2014, March 2021. In May 2016, May 2021. In May 2020, Taurus4757 In March 2021, The following table summarizes warrant activity for the nine September 30, 2022 2021: Nine Months Ended September 30, 2022 2021 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Beginning balance - $ - 79,100 $ 4.75 Exercised - - (79,100 ) 4.75 Ending balance - $ - - $ -

Note 13 - Revenue

Note 13 - Revenue	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	13. To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five may not 30 90 three nine September 30, 2022, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of cell processing tools, freezers, thawing devices, and cold chain products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statements of Operations. Service revenue is generated from the storage of biological and pharmaceutical materials. We recognize service revenue over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC Topic 606, not one None three nine September 30, 2022. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems within its storage and storage services product line to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Applying the practical expedient from ASC Topic 842, None None Embedded Leases may 842 Total bioproduction tools and services revenue for the three nine September 30, 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except percentages) 2022 2021 2022 2021 Product revenue Freezer and thaw $ 15,326 $ 17,610 $ 49,331 $ 40,021 Cell processing 18,082 11,505 48,336 30,131 Storage and storage services 260 86 560 293 Service revenue Storage and storage services 4,312 2,250 11,099 6,417 Cell processing 18 - 18 - Rental revenue Storage and storage services 2,749 2,349 8,156 4,989 Total revenue $ 40,747 $ 33,800 $ 117,500 $ 81,851 The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not one 2014 09, Revenue from Contracts with Customers not one September 30, 2022. The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts: Year Ending December 31, (In thousands) 2022 (3 months remaining) 2023 2024 Total Rental revenue $ 1,809 $ 3,735 $ 900 $ 6,444 Service revenue $ 69 $ 191 $ 10 $ 270

Note 14 - Share-based Compensat

Note 14 - Share-based Compensation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	14. Share-based compensation Service vesting-based stock options The following is a summary of service vesting-based stock option activity for the September 30, 2022, September 30, 2022: Nine Months Ended September 30, 2022 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 624,531 $ 2.13 Exercised (158,075 ) 1.94 Forfeited (10,000 ) 1.82 Outstanding as of September 30, 2022 456,456 $ 2.20 Stock options exercisable as of September 30, 2022 456,456 $ 2.20 We recognized stock compensation expense related to service-based options of zero three nine September 30, 2022 three nine September 30, 2021, September 30, 2022, September 30, 2022. three nine September 30, 2022, three nine September 30, 2021, three nine September 30, 2022. September 30, 2022 September 30, 2022. Performance-based stock options No three nine September 30, 2022 2021 three nine September 30, 2022. three nine 2021, three nine September 30, 2022 2021. Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the nine September 30, 2022, September 30, 2022: Nine Months Ended September 30, 2022 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,212,783 $ 37.48 Granted 1,255,449 25.55 Vested (448,056 ) 35.60 Forfeited (83,922 ) 46.29 Non-vested as of September 30, 2022 1,936,254 $ 29.79 The aggregate fair value of the service vesting-based awards granted was $23.3 million and $32.1 million during the three nine September 30, 2022, three nine September 30, 2021, three nine September 30, 2022, three nine September 30, 2021, We recognized stock compensation expense related to service vesting-based awards of $5.1 million and $14.6 million during the three nine September 30, 2022, three nine September 30, 2021, September 30, 2022, Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the nine September 30, 2022 September 30, 2022: Nine Months Ended September 30, 2022 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 139,756 $ 19.86 Granted 349,568 21.26 Vested (218,280 ) 10.95 Non-vested as of September 30, 2022 271,044 $ 30.64 On March 25, 2020, February 24, 2022, January 1, 2020 December 31, 2021 20 0% 2 December 31, 2021. On February 8, 2021, January 1, 2021 December 31, 2022 20 0% December 31, 2022. On February 24, 2022, January 1, 2022 December 31, 2023 20 0% December 31, 2023. We recognized stock compensation expense of $1.2 million and $3.1 million related to market-based restricted stock awards for the three nine September 30, 2022, three nine September 30, 2021, September 30, 2022, The aggregate fair value of the market-based awards granted was zero three nine September 30, 2022, zero three nine September 30, 2021, zero three nine September 30, 2022, zero three nine September 30, 2021, Total stock compensation expense We recorded total stock compensation expense for the three nine September 30, 2022 2021, Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of revenue $ 809 $ 742 $ 2,619 $ 1,047 General and administrative costs 3,959 3,015 10,687 5,662 Sales and marketing costs 829 560 2,272 1,012 Research and development costs 702 551 2,093 1,171 Total $ 6,299 $ 4,868 $ 17,671 $ 8,892

Note 15 - Acquisitions

Note 15 - Acquisitions	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Business Combination Disclosure [Text Block]	15. Sexton acquisition General terms and effects On August 9, 2021, On September 1, 2021, Total consideration transferred (in thousands, except number of shares and stock price): Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 Plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 Less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 Transaction costs related to the acquisition are expensed as incurred and are not Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Sexton were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $509,000. Of the acquired accounts receivable, $17,000 is estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 1,516 Accounts receivable, net 492 Inventories 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Sexton’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $28.5 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Global Cooling acquisition General terms and effects On March 19, 2021, On May 3, 2021, Merger consideration The aggregate merger consideration paid pursuant to the GCI Merger Agreement to the GCI Stockholders was 6,646,870 newly issued shares of common stock, provided, however, that the GCI Merger Consideration otherwise payable to GCI Stockholders is subject to the withholding of the GCI Escrow Shares (as defined below) and is subject to reduction for indemnification obligations. The GCI Merger Consideration allocable to one 805, not Total consideration transferred (in thousands, except number of shares, stock price, and consideration percentage): BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Transaction costs related to the acquisition are expensed as incurred and are not Escrow shares At the GCI Closing, approximately nine The GCI Escrow Property will be held for a period of up to twenty-four Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Global Cooling were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $7.1 million. Of the acquired accounts receivable, $53,000 was estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 43 Accounts receivable, net 7,076 Inventories 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Global Cooling’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not In July 2022, June 30, 2022 8 Goodwill and intangible assets Acquired goodwill The goodwill of $137.8 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Pro forma presentation The following unaudited pro forma financial information presents the combined results of operations of Sexton as if the acquisition had occurred on January 1, 2021 Three Months Nine Months 2021 2021 (In thousands) (unaudited) (unaudited) Total revenue $ 34,524 $ 85,189 Net (loss) income $ (685 ) $ 4,612 The following unaudited pro forma financial information presents the combined results of operations of Global Cooling as if the acquisition had occurred on January 1, 2021 Three Months Nine Months 2021 2021 (In thousands) (unaudited) (unaudited) Total revenue $ 33,800 $ 106,427 Net (loss) income $ 79 $ (1,939 )

Note 16 - Income Taxes

Note 16 - Income Taxes	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	16. The Company accounts for income taxes under ASC Topic 740 The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. The income tax benefit of $4.9 million for the nine September 30, 2022 $4.9 The Company’s US projected effective income tax rate without discrete items was 5%, which is lower than the US federal statutory rate of 21% primarily due to the impact of a projected partial valuation allowance on net operating loss carryforwards and non-deductible executive compensation offset by state tax benefits and research tax credits. Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates both positive and negative evidence when concluding whether it is more likely than not

Note 17 - Net (Loss) Income Per

Note 17 - Net (Loss) Income Per Common Share	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	17. The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except share and earnings per share data) 2022 2021 2022 2021 Basic earnings (loss) per common share Numerator: Net (loss) income $ (9,957 ) $ 79 $ (89,577 ) $ 6,837 Amount attributable to unvested restricted shares - (2 ) - (212 ) Amount attributable to warrants outstanding - - - (4 ) Net (loss) income allocated to common shareholders (9,957 ) 77 (89,577 ) 6,621 Denominator: Weighted-average common shares issued and outstanding 42,647,967 40,911,801 42,376,392 37,435,224 Basic (loss) earnings per common share $ (0.23 ) $ 0.00 $ (2.11 ) $ 0.18 Diluted earnings (loss) per common share Numerator: Net (loss) income $ (9,957 ) $ 79 $ (89,577 ) $ 6,837 Amount attributable to unvested restricted shares - (2 ) - (205 ) Amount attributable to warrants - - - (4 ) Diluted (loss) earnings per common share (9,957 ) 77 (89,577 ) 6,628 Denominator: Weighted-average common shares issued and outstanding 42,647,967 40,911,801 42,376,392 37,435,224 Dilutive potential common shares from: Stock options - 1,069,207 - 1,330,207 Restricted shares - 1,315,462 - 1,195,154 Warrants - - - 24,338 Diluted weighted average shares issued and outstanding 42,647,967 43,296,470 42,376,392 39,984,923 Diluted (loss) earnings per common share $ (0.23 ) $ 0.00 $ (2.11 ) $ 0.17 The following table sets forth the number of weighted-average common shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Stock options and restricted stock awards 2,022,405 - 2,678,601 - Total 2,022,405 - 2,678,601 -

Note 18 - Commitments and Conti

Note 18 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	18. Employment agreements We have employment agreements with certain key employees. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none may not Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not September 30, 2022.

Note 19 - Employee Benefit Plan

Note 19 - Employee Benefit Plan	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Defined Contribution Plan [Text Block]	19. The Company sponsors 401 may three nine September 30, 2022, three nine September 30, 2021,

Note 20 - Subsequent Events

Note 20 - Subsequent Events	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	20. On September 28, 2022, October 1, 2022 January 31, 2030.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the recoverability of the Company’s deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The Unaudited Condensed Consolidated Financial Statements included herein have been prepared by BioLife in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10 10 X not 10 December 31, 2021. The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU” acquired on August 8, 2019), November 12, 2019), October 1, 2020), April 1, 2021), May 3, 2021), September 1, 2021). In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheet, Unaudited Condensed Consolidated Statements of Operations, Unaudited Condensed Consolidated Statements of Shareholders’ Equity, and Unaudited Condensed Consolidated Statements of Cash Flows into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity.
Segment Reporting, Policy [Policy Text Block]	Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one
Significant Accounting Policies [Policy Text Block]	Significant accounting policies The following describes an update to the Company’s accounting policies for investments. For a full discussion of significant accounting policies, including additional information regarding the Company’s accounting policies for investments, refer to the Notes to the Consolidated Financial Statements included within the Company’s Annual Report on Form 10 December 31, 2021. The Company classifies its investment in marketable debt securities as “available-for-sale.” Available-for-sale securities are carried at fair value with unrealized holding gains or losses recorded in other comprehensive income, net of tax. Gains or losses are included in earnings in the period in which they are realized. The cost of securities sold is determined based on the specific identification method. The cost of available-for-sale debt securities is adjusted for premiums and discounts, with the accretion or amortization of such amounts included as a portion of interest. Available-for-sale debt securities with an original maturity date less than one one
Liquidity and Capital Resources, Policy [Policy Text Block]	Liquidity and capital resources On September 30, 2022 December 31, 2021, 2022 3. 11 2022 3. twelve 10 may may not
Risk and Uncertainties, Policy [Policy Text Block]	Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” In the nine September 30, 2022 December 31, 2021, 19 not 19 19. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk and business risk Significant customers are those that represent more than 10% Accounts Receivable Revenue September 30, December 31, Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 2022 2021 Customer A 22 % 21 % * * * * Customer B 10 % 11 % 17 % 19 % 19 % 14 % * less than 10% Revenue from foreign customers is denominated in United States dollars or euros. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Nine Months Ended September 30, September 30, Revenue by customers geographic locations 2022 2021 2022 2021 United States 69 % 82 % 74 % 80 % Europe, Middle East, Africa (EMEA) 20 % 9 % 18 % 10 % Canada 8 % 6 % 5 % 7 % Other 3 % 3 % 3 % 3 % Total revenue 100 % 100 % 100 % 100 % In the three nine September 30, 2022 2021, no 10% As of September 30, 2022 December 31, 2021,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In June 2022, No. 2022 03, Fair Value Measurements (Topic 820 820” 2022 03 1 820, 2 3 820. 2022 03 not not December 15, 2023, 2022 03. not In March 2022, No. 2022 02 Financial Instruments-Credit Losses (Topic 326 2022 02 2022 02 326 2022 02 December 15, 2022 2022 02

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Accounts Receivable Revenue September 30, December 31, Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 2022 2021 Customer A 22 % 21 % * * * * Customer B 10 % 11 % 17 % 19 % 19 % 14 %
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, Revenue by customers geographic locations 2022 2021 2022 2021 United States 69 % 82 % 74 % 80 % Europe, Middle East, Africa (EMEA) 20 % 9 % 18 % 10 % Canada 8 % 6 % 5 % 7 % Other 3 % 3 % 3 % 3 % Total revenue 100 % 100 % 100 % 100 %

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of September 30, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 22,868 $ - $ - $ 22,868 Available-for-sale securities: U.S. government securities 13,054 - - 13,054 Corporate debt securities - 20,094 - 20,094 Other debt securities - 1,925 - 1,925 Total 35,922 22,019 - 57,941 Liabilities: Contingent consideration - business combinations - - 5,862 5,862 Debt - 26,274 - 26,274 Total $ - $ 26,274 $ 5,862 $ 32,136 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Debt - 7,215 - 7,215 Total $ - $ 7,215 $ 10,027 $ 17,242
Warrant Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance as of December 31, 2021 and 2020 $ - $ 2,780 Exercised warrants - (2,901 ) Change in fair value recognized in net (loss) income - 121 Ending balance $ - $ -
Contingent Consideration Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance as of December 31, 2021 and 2020 $ 10,027 $ 7,152 Change in fair value recognized in net (loss) income (3,348 ) 1,086 Payment of contingent consideration earned (817 ) - Ending balance $ 5,862 $ 8,238

Note 3 - Investments (Tables)

Note 3 - Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Debt Securities, Available-for-Sale [Table Text Block]	September 30, 2022 Amortized Gross unrealized Estimated (In thousands) Cost Gains Losses Fair Value Available-for-sale securities, current portion U.S. government securities $ 13,102 $ - $ 48 $ 13,054 Corporate debt securities 20,112 - 18 20,094 Other debt securities 1,444 - 9 1,435 Total short-term 34,658 - 75 34,583 Available-for-sale securities, long-term Other debt securities 490 - - 490 Total marketable securities $ 35,148 $ - $ 75 $ 35,073 Amortized Estimated (In thousands) Cost Fair Value Due in one year or less $ 34,658 $ 34,583 Due after one year through five years 490 490 Total $ 35,148 $ 35,073

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) 2022 2021 Raw materials $ 18,241 $ 17,252 Work in progress 5,454 5,015 Finished goods 10,052 6,078 Total $ 33,747 $ 28,345

Note 5 - Leases (Tables)

Note 5 - Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block]	September 30, December 31, (In thousands) 2022 2021 Weighted average discount rate - operating leases 3.8 % 3.8 % Weighted average discount rate - finance leases 6.1 % 6.1 % Weighted average remaining lease term in years - operating leases 7.3 7.8 Weighted average remaining lease term in years - finance leases 2.3 3.0
Lease, Cost [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2022 2021 2022 2021 Operating lease costs $ 909 $ 805 $ 2,745 $ 1,998 Short-term lease costs 534 498 1,627 1,158 Total operating lease costs 1,443 1,303 4,372 3,156 Variable lease costs 250 193 809 477 Total lease costs $ 1,693 $ 1,496 $ 5,181 $ 3,633
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(In thousands) Operating Leases Financing Leases 2022 (3 months remaining) $ 1,014 $ 43 2023 3,158 171 2024 2,882 101 2025 2,428 28 2026 1,997 2 Thereafter 8,278 - Total lease payments 19,757 345 Less: interest (2,514 ) (23 ) Total present value of lease liabilities $ 17,243 $ 322

Note 6 - Assets Held for Rent (

Note 6 - Assets Held for Rent (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Scheduleof Assets Held for Rent [Table Text Block]	(In thousands) 2022 2021 Shippers placed in service $ 7,375 $ 5,645 Fixed assets held for rent 4,686 4,040 Accumulated depreciation (4,571 ) (2,272 ) Net 7,490 7,413 Shippers and related components in production 1,867 2,396 Total $ 9,357 $ 9,809

Note 7 - Property and Equipme_2

Note 7 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, (In thousands) 2022 2021 Property and equipment Leasehold improvements $ 5,069 $ 3,840 Furniture and computer equipment 1,874 1,861 Manufacturing and other equipment 19,715 16,675 Construction in-progress 3,767 2,022 Subtotal 30,425 24,398 Less: Accumulated depreciation (8,688 ) (6,741 ) Property and equipment, net $ 21,737 $ 17,657

Note 8 - Goodwill and Intangi_2

Note 8 - Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(In thousands, except weighted average useful life) September 30, 2022 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 15,984 $ (3,539 ) $ 12,445 9.6 Tradenames 29,635 (4,091 ) 25,544 13.1 Technology - acquired 38,410 (12,063 ) 26,347 5.1 Non-compete agreements 1,986 (856 ) 1,130 2.3 In-process research and development (1) 8,547 - 8,547 N/A Total intangible assets $ 94,562 $ (20,549 ) $ 74,013 9.0 (In thousands, except weighted average useful life) December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development (1) 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(In thousands) Amortization For the Years Ending December 31, Expense 2022 (3 months remaining) $ 2,494 2023 9,570 2024 8,745 2025 8,398 2026 7,975 Thereafter 28,284 Total $ 65,466

Note 9 - Accrued Expenses and_2

Note 9 - Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Other Current Liabilities [Table Text Block]	September 30, December 31, (In thousands) 2022 2021 Accrued compensation $ 4,706 $ 4,351 Accrued expenses 1,470 1,656 Deferred revenue, current 429 814 Accrued taxes 1,151 27 Other 22 294 Total accrued expenses and other current liabilities $ 7,778 $ 7,142

Note 10 - Warranty Reserve Li_2

Note 10 - Warranty Reserve Liability (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Nine Months Ended September 30, (In thousands) 2022 2021 Beginning balance as of December 31, 2021 and 2020 $ 9,398 $ 212 Warranty reserve acquired in the acquisition of Global Cooling - 3,353 Provision for warranties 1,770 4,446 Settlements of warranty claims (2,801 ) (2,459 ) Ending Balance $ 8,367 $ 5,552

Note 11 - Long-term Debt (Table

Note 11 - Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Debt [Table Text Block]	September 30, December 31, (In thousands) Maturity Date Interest Rate 2022 2021 2022 term loan 1 (1) 4.0 % $ - $ 1,750 2022 term loan 2 Various 4.0 % 2,896 2,813 2022 term loan 3 Jun-26 6.8 % 20,000 - Insurance premium financing Apr-23 5.0 % 1,635 373 Freezer equipment loan Dec-25 5.7 % 502 612 Manufacturing equipment loans Oct-25 5.7 % 288 355 Freezer installation loan Various 6.3 % 1,143 1,334 Other loans Various Various 8 9 Total debt, excluding unamortized debt issuance costs 26,472 7,246 Less: unamortized debt issuance costs (198 ) (31 ) Total debt 26,274 7,215 Less: current portion (2,067 ) (862 ) Total long-term debt $ 24,207 $ 6,353
Schedule of Maturities of Long-Term Debt [Table Text Block]	(In thousands) Amount 2022 (3 months remaining) $ 679 2023 1,888 2024 5,544 2025 10,543 2026 5,222 Thereafter 2,596 Total debt, excluding unamortized debt issuance costs 26,472 Less: unamortized debt issuance costs (198 ) Total debt $ 26,274

Note 12 - Warrants (Tables)

Note 12 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Nine Months Ended September 30, 2022 2021 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Beginning balance - $ - 79,100 $ 4.75 Exercised - - (79,100 ) 4.75 Ending balance - $ - - $ -

Note 13 - Revenue (Tables)

Note 13 - Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Revenues By Product Line [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except percentages) 2022 2021 2022 2021 Product revenue Freezer and thaw $ 15,326 $ 17,610 $ 49,331 $ 40,021 Cell processing 18,082 11,505 48,336 30,131 Storage and storage services 260 86 560 293 Service revenue Storage and storage services 4,312 2,250 11,099 6,417 Cell processing 18 - 18 - Rental revenue Storage and storage services 2,749 2,349 8,156 4,989 Total revenue $ 40,747 $ 33,800 $ 117,500 $ 81,851
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Year Ending December 31, (In thousands) 2022 (3 months remaining) 2023 2024 Total Rental revenue $ 1,809 $ 3,735 $ 900 $ 6,444 Service revenue $ 69 $ 191 $ 10 $ 270

Note 14 - Share-based Compens_2

Note 14 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30, 2022 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 624,531 $ 2.13 Exercised (158,075 ) 1.94 Forfeited (10,000 ) 1.82 Outstanding as of September 30, 2022 456,456 $ 2.20 Stock options exercisable as of September 30, 2022 456,456 $ 2.20
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Nine Months Ended September 30, 2022 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,212,783 $ 37.48 Granted 1,255,449 25.55 Vested (448,056 ) 35.60 Forfeited (83,922 ) 46.29 Non-vested as of September 30, 2022 1,936,254 $ 29.79 Nine Months Ended September 30, 2022 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 139,756 $ 19.86 Granted 349,568 21.26 Vested (218,280 ) 10.95 Non-vested as of September 30, 2022 271,044 $ 30.64
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of revenue $ 809 $ 742 $ 2,619 $ 1,047 General and administrative costs 3,959 3,015 10,687 5,662 Sales and marketing costs 829 560 2,272 1,012 Research and development costs 702 551 2,093 1,171 Total $ 6,299 $ 4,868 $ 17,671 $ 8,892

Note 15 - Acquisitions (Tables)

Note 15 - Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 Plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 Less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash $ 1,516 Accounts receivable, net 492 Inventories 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 Cash $ 43 Accounts receivable, net 7,076 Inventories 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Nine Months 2021 2021 (In thousands) (unaudited) (unaudited) Total revenue $ 34,524 $ 85,189 Net (loss) income $ (685 ) $ 4,612 Three Months Nine Months 2021 2021 (In thousands) (unaudited) (unaudited) Total revenue $ 33,800 $ 106,427 Net (loss) income $ 79 $ (1,939 )

Note 17 - Net (Loss) Income P_2

Note 17 - Net (Loss) Income Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except share and earnings per share data) 2022 2021 2022 2021 Basic earnings (loss) per common share Numerator: Net (loss) income $ (9,957 ) $ 79 $ (89,577 ) $ 6,837 Amount attributable to unvested restricted shares - (2 ) - (212 ) Amount attributable to warrants outstanding - - - (4 ) Net (loss) income allocated to common shareholders (9,957 ) 77 (89,577 ) 6,621 Denominator: Weighted-average common shares issued and outstanding 42,647,967 40,911,801 42,376,392 37,435,224 Basic (loss) earnings per common share $ (0.23 ) $ 0.00 $ (2.11 ) $ 0.18 Diluted earnings (loss) per common share Numerator: Net (loss) income $ (9,957 ) $ 79 $ (89,577 ) $ 6,837 Amount attributable to unvested restricted shares - (2 ) - (205 ) Amount attributable to warrants - - - (4 ) Diluted (loss) earnings per common share (9,957 ) 77 (89,577 ) 6,628 Denominator: Weighted-average common shares issued and outstanding 42,647,967 40,911,801 42,376,392 37,435,224 Dilutive potential common shares from: Stock options - 1,069,207 - 1,330,207 Restricted shares - 1,315,462 - 1,195,154 Warrants - - - 24,338 Diluted weighted average shares issued and outstanding 42,647,967 43,296,470 42,376,392 39,984,923 Diluted (loss) earnings per common share $ (0.23 ) $ 0.00 $ (2.11 ) $ 0.17
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Stock options and restricted stock awards 2,022,405 - 2,678,601 - Total 2,022,405 - 2,678,601 -

Note 1 - Organization and Sig_3

Note 1 - Organization and Significant Accounting Policies (Details Textual) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Cash, Cash Equivalents, and Short-Term Investments, Total	$ 62.1	$ 69.9
Supplier Concentration Risk [Member] | Accounts Payable [Member]
Number of Suppliers	1	1
Supplier Concentration Risk [Member] | Accounts Payable [Member] | One Supplier [Member]
Concentration Risk, Percentage	11%	10%
The 2022 Term Loan 3 [Member]
Debt Instrument, Maximum Borrowing Capacity at Closing	$ 30

Note 1 - Organization and Sig_4

Note 1 - Organization and Significant Accounting Policies - Significant Customers (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accounts Receivable [Member] | Customer A [Member]
Concentration by customer			22%		21%
Accounts Receivable [Member] | Customer B [Member]
Concentration by customer			10%		11%
Revenue Benchmark [Member] | Customer B [Member]
Concentration by customer	17%	19%	19%	14%

Note 1 - Organization and Sig_5

Note 1 - Organization and Significant Accounting Policies - Concentrations Risk by Geographic Locations (Details) - Revenue Benchmark [Member] - Geographic Concentration Risk [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
UNITED STATES
Revenue by customers' geographic locations, percentage	69%	82%	74%	80%
EMEA [Member]
Revenue by customers' geographic locations, percentage	20%	9%	18%	10%
CANADA
Revenue by customers' geographic locations, percentage	8%	6%	5%	7%
Geographic, Other [Member]
Revenue by customers' geographic locations, percentage	3%	3%	3%	3%
All Location [Member]
Revenue by customers' geographic locations, percentage	100%	100%	100%	100%

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurement (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Oct. 01, 2020 USD ($)	Nov. 10, 2019
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ 2,346,000	$ (140,000)	$ (3,348,000)	$ 1,086,000
CBS Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Total					$ 140,000
CBS Acquisition [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input					0.210		0.260
CBS Acquisition [Member] | Measurement Input, Risk Free Interest Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input					0.0023		0.0174
CBS Acquisition [Member] | Measurement Input, Price Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input					0.63		0.70
SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Total	5,700,000		5,700,000		$ 9,900,000	$ 3,700,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ (2,300,000)	$ 141,000	$ 3,300,000	$ (1,200,000)
Business Combination, Contingent Consideration, Stock Issued (in shares) | shares	64,130
SciSafe Holdings, Inc [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	12.5		12.5			0.045
SciSafe Holdings, Inc [Member] | Measurement Input, Risk Free Interest Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	4.1		4.1			0.0020
SciSafe Holdings, Inc [Member] | Measurement Input, Asset Price Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	66		66			0.60
SciSafe Holdings, Inc [Member] | Measurement Input, Revenue Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	30		30			0.15

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurement - Financial Assets and Liabilities on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Marketable debt securities	$ 35,073
Fair Value, Recurring [Member]
Assets	57,941	$ 63,873
Contingent consideration - business combinations	5,862	10,027
Debt	26,274	7,215
Liabilities	32,136	17,242
Fair Value, Recurring [Member] | US Government Agencies Debt Securities [Member]
Marketable debt securities	13,054
Fair Value, Recurring [Member] | Other Debt Obligations [Member]
Marketable debt securities	1,925
Fair Value, Recurring [Member] | Money Market Funds [Member]
Cash equivalents	22,868	63,873
Fair Value, Recurring [Member] | Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	20,094
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets	35,922	63,873
Contingent consideration - business combinations	0	0
Debt	0	0
Liabilities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]
Marketable debt securities	13,054
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Other Debt Obligations [Member]
Marketable debt securities	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Cash equivalents	22,868	63,873
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets	22,019	0
Contingent consideration - business combinations	0	0
Debt	26,274	7,215
Liabilities	26,274	7,215
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Marketable debt securities	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Other Debt Obligations [Member]
Marketable debt securities	1,925
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Cash equivalents	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	20,094
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets	0	0
Contingent consideration - business combinations	5,862	10,027
Debt	0	0
Liabilities	5,862	10,027
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member]
Marketable debt securities	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Other Debt Obligations [Member]
Marketable debt securities	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Cash equivalents	0	$ 0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	$ 0

Note 2 - Fair Value Measureme_5

Note 2 - Fair Value Measurement - Fair Value of Contingent Consideration Using Level 3 Inputs (Details) - Contingent Consideration Liabilities [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Beginning balance as of December 31, 2021 and 2020	$ 10,027	$ 7,152
Change in fair value recognized in net (loss) income	(3,348)	1,086
Payment of contingent consideration earned	(817)	0
Ending balance	$ 5,862	$ 8,238

Note 2 - Fair Value Measureme_6

Note 2 - Fair Value Measurement - Fair Value of Warrant Liabilities Using Level 3 Inputs (Details) - Warrant Liabilities [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Beginning balance as of December 31, 2021 and 2020	$ 0	$ 2,780
Exercised warrants	0	(2,901)
Change in fair value recognized in net (loss) income	0	121
Ending balance	$ 0	$ 0

Note 3 - Investments (Details T

Note 3 - Investments (Details Textual) - Contingent Convertible Preferred Stock [Member] - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Series A-1 and A-2, Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount	$ 4,100,000	$ 3,400,000
Series E Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount	$ 995,000	$ 995,000

Note 3 - Investments - Availabl

Note 3 - Investments - Available-For-Sale Marketable Securities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-Sale, Amortized Cost, Current	$ 34,658,000
Debt Securities, Available-for-Sale, Unrealized Loss, Current	75,000
Available-for-sale securities, current portion	34,583,000	$ 0
Debt Securities, Available-for-Sale, Amortized Cost, NoncurrentDebt Securities, Available-for-Sale, Amortized Cost, Noncurrent	490,000
Available-for-sale securities, long-term	490,000	0
Debt Securities, Available-for-Sale, Amortized Cost, Total	35,148,000
Total marketable securities	75,000
Debt Securities, Available-for-Sale, Total	35,073,000
Due in one year or less	34,658,000
Due in one year or less	34,583,000	$ 0
Due after one year through five years	490,000
Due after one year through five years	490,000
Total	35,148,000
Marketable debt securities	35,073,000
US Government Agencies Debt Securities [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	13,102,000
Debt Securities, Available-for-Sale, Unrealized Loss, Current	48,000
Available-for-sale securities, current portion	13,054
Due in one year or less	13,102,000
Due in one year or less	13,054
Corporate Debt Securities [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	20,112,000
Debt Securities, Available-for-Sale, Unrealized Loss, Current	18,000
Available-for-sale securities, current portion	20,094,000
Due in one year or less	20,112,000
Due in one year or less	20,094,000
Other Debt Obligations [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	1,444,000
Debt Securities, Available-for-Sale, Unrealized Loss, Current	9,000
Available-for-sale securities, current portion	1,435,000
Debt Securities, Available-for-Sale, Amortized Cost, NoncurrentDebt Securities, Available-for-Sale, Amortized Cost, Noncurrent	490,000
Debt Securities, Available-for-Sale, Unrealized Loss, Noncurrent	0
Available-for-sale securities, long-term	490,000
Due in one year or less	1,444,000
Due in one year or less	1,435,000
Due after one year through five years	$ 490,000

Note 4 - Inventory - Summary of

Note 4 - Inventory - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Raw materials	$ 18,241	$ 17,252
Work in progress	5,454	5,015
Finished goods	10,052	6,078
Total	$ 33,747	$ 28,345

Note 5 - Leases (Details Textua

Note 5 - Leases (Details Textual)	Sep. 30, 2022
Maximum [Member] | Real Estate Lease[Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	10 years
Maximum [Member] | Lease Extensions [Member]
Lessee, Operating Lease, Term of Contract (Year)	5 years
Minimum [Member] | Real Estate Lease[Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	1 year
Minimum [Member] | Lease Extensions [Member]
Lessee, Operating Lease, Term of Contract (Year)	1 year

Note 5 - Leases - Lease Term an

Note 5 - Leases - Lease Term and Discount Rate (Details)	Sep. 30, 2022	Dec. 31, 2021
Weighted average discount rate - operating leases	3.80%	3.80%
Weighted average discount rate - finance leases	6.10%	6.10%
Weighted average remaining lease term in years - operating leases (Year)	7 years 3 months 18 days	7 years 9 months 18 days
Weighted average remaining lease term in years - finance leases (Year)	2 years 3 months 18 days	3 years

Note 5 - Leases - Components of

Note 5 - Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating lease costs	$ 909	$ 805	$ 2,745	$ 1,998
Short-term lease costs	534	498	1,627	1,158
Total operating lease costs	1,443	1,303	4,372	3,156
Variable lease costs	250	193	809	477
Total lease costs	$ 1,693	$ 1,496	$ 5,181	$ 3,633

Note 5 - Leases - Maturities of

Note 5 - Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
2022 (6 months remaining), operating leases	$ 1,014
2022 (6 months remaining), finance leases	43
2023, operating leases	3,158
2023, finance leases	171
2024, operating leases	2,882
2024, finance leases	101
2025, operating leases	2,428
2025, finance leases	28
2026, operating leases	1,997
2026, finance leases	2
Thereafter, operating leases	8,278
Thereafter, finance leases	0
Total operating lease payments	19,757
Total financing lease payments, finance leases	345
Less: operating lease interest	(2,514)
Less: financing lease interest	(23)
Total present value of operating lease liabilities	17,243
Total present value of financing lease liabilities	$ 322

Note 6 - Assets Held for Rent_2

Note 6 - Assets Held for Rent (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Assets Held for Rent, Depreciation	$ 921,000	$ 410,000	$ 2,700,000	$ 873,000

Note 6 - Assets Held for Rent -

Note 6 - Assets Held for Rent - Assets Held for Rent (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Shippers placed in service	$ 7,375	$ 5,645
Fixed assets held for rent	4,686	4,040
Accumulated depreciation	(4,571)	(2,272)
Net	7,490	7,413
Shippers and related components in production	1,867	2,396
Total	$ 9,357	$ 9,809

Note 7 - Property and Equipme_3

Note 7 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Depreciation, Total	$ 865,000	$ 691,000	$ 2,400,000	$ 2,100,000

Note 7 - Property and Equipme_4

Note 7 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property and equipment	$ 30,425	$ 24,398
Less: Accumulated depreciation	(8,688)	(6,741)
Property and equipment, net	21,737	17,657
Leasehold Improvements [Member]
Property and equipment	5,069	3,840
Furniture and Computer Equipment [Member]
Property and equipment	1,874	1,861
Manufacturing Facility [Member]
Property and equipment	19,715	16,675
Construction in Progress [Member]
Property and equipment	$ 3,767	$ 2,022

Note 8 - Goodwill and Intangi_3

Note 8 - Goodwill and Intangible Assets (Details Textual) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Amortization of Intangible Assets	$ 2,513,000		$ 2,525,000	$ 8,236,000	$ 5,340,000
Finite-Lived Intangible Assets, Net, Ending Balance	65,466,000			65,466,000
Abandoned In Process Research and Development [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		$ 8,000,000
In Process Research and Development Not Related to Abandonment [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		50,900,000
Finite-Lived Intangible Assets, Net, Ending Balance						$ 59,400,000
Technology-Based Intangible Assets [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		3,500,000
Finite-Lived Intangible Assets, Net, Ending Balance	26,347,000			26,347,000		31,200,000	$ 34,153,000
Customer Relationships [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		1,500,000
Finite-Lived Intangible Assets, Net, Ending Balance	12,445,000			12,445,000		14,500,000	15,740,000
Trade Names [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		5,900,000
Finite-Lived Intangible Assets, Net, Ending Balance	25,544,000			25,544,000		32,000,000	33,268,000
Noncompete Agreements [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		$ 4,000
Finite-Lived Intangible Assets, Net, Ending Balance	$ 1,130,000			$ 1,130,000		$ 1,300,000	$ 1,548,000

Note 8 - Goodwill and Intangi_4

Note 8 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022		Dec. 31, 2021	Mar. 31, 2022
Accumulated Amortization	$ (20,549)		$ (12,313)
Net Carrying Value	65,466
Total intangible assets, gross	94,562		164,462
Total intangible assets, net	$ 74,013		$ 152,149
Weighted Average [Member]
Weighted Average Useful Life (Year)	9 years		9 years 9 months 18 days
Customer Relationships [Member]
Gross Carrying Value	$ 15,984		$ 17,516
Accumulated Amortization	(3,539)		(1,776)
Net Carrying Value	$ 12,445		$ 15,740	$ 14,500
Customer Relationships [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)	9 years 7 months 6 days		10 years 3 months 18 days
Trade Names [Member]
Gross Carrying Value	$ 29,635		$ 35,574
Accumulated Amortization	(4,091)		(2,306)
Net Carrying Value	$ 25,544		$ 33,268	32,000
Trade Names [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)	13 years 1 month 6 days		13 years 9 months 18 days
Technology-Based Intangible Assets [Member]
Gross Carrying Value	$ 38,410		$ 41,942
Accumulated Amortization	(12,063)		(7,789)
Net Carrying Value	$ 26,347		$ 34,153	31,200
Technology-Based Intangible Assets [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)	5 years 1 month 6 days		5 years 10 months 24 days
Noncompete Agreements [Member]
Gross Carrying Value	$ 1,986		$ 1,990
Accumulated Amortization	(856)		(442)
Net Carrying Value	$ 1,130		$ 1,548	$ 1,300
Noncompete Agreements [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)	2 years 3 months 18 days		3 years
In Process Research and Development [Member]
Gross Carrying Value	$ 8,547	[1]	$ 67,440
Accumulated Amortization			0
Net Carrying Value	$ 8,547	[1]	$ 67,440
[1]In-process R&D represents the fair value of incomplete research and development that has not yet reached technological feasibility. We will amortize the asset upon technological feasibility.

Note 8 - Goodwill and Intangi_5

Note 8 - Goodwill and Intangible Assets - Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2022 USD ($)
2022 (3 months remaining)	$ 2,494
2023	9,570
2024	8,745
2025	8,398
2026	7,975
Thereafter	28,284
Total	$ 65,466

Note 9 - Accrued Expenses and_3

Note 9 - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued compensation	$ 4,706	$ 4,351
Accrued expenses	1,470	1,656
Deferred revenue, current	429	814
Accrued taxes	1,151	27
Other	22	294
Total accrued expenses and other current liabilities	$ 7,778	$ 7,142

Note 10 - Warranty Reserve Li_3

Note 10 - Warranty Reserve Liability - Schedule of Warranty Liability (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Beginning balance as of December 31, 2021 and 2020	$ 9,398	$ 212
Warranty reserve acquired in the acquisition of Global Cooling	0	3,353
Provision for warranties	1,770	4,446
Settlements of warranty claims	(2,801)	(2,459)
Ending Balance	$ 8,367	$ 5,552

Note 11 - Long-term Debt (Detai

Note 11 - Long-term Debt (Details Textual) - The 2022 Term Loan 3 [Member] $ in Millions	Sep. 30, 2022 USD ($)
Debt Instrument, Maximum Borrowing Capacity	$ 50
Debt Instrument, Maximum Borrowing Capacity at Closing	30
Debt Instrument, Additional Maximum Amount Within Nine Months After Closing	10
Debt Instrument, Face Amount	$ 20
Debt Instrument, Interest Rate, Maximum Stated Percentage for Each Tranche Borrowed	1%
Debt Instrument, Additional Maximum Amount Upon Certain Milestone Acheivements	$ 10
Debt Instrument, Additional Maximum At Discretion of Lender	$ 10
Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%

Note 11 - Long-term Debt - Long

Note 11 - Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt, carrying amount	$ 26,472	$ 7,246
Less: unamortized debt issuance costs	(198)	(31)
Total debt	26,274	7,215
Less: current portion	(2,067)	(862)
Total long-term debt	$ 24,207	6,353
The 2022 Term Loan 1 [Member]
Interest rate	4%
Debt, carrying amount	$ 0	1,750
The 2022 Term Loan 2 [Member]
Interest rate	4%
Debt, carrying amount	$ 2,896	2,813
The 2022 Term Loan 3 [Member]
Interest rate	6.80%
Debt, carrying amount	$ 20,000	0
Financed Insurance Premium [Member]
Interest rate	5%
Debt, carrying amount	$ 1,635	373
Freezer Equipment Loan [Member]
Interest rate	5.70%
Debt, carrying amount	$ 502	612
Manufacturing Equipment Loans [Member]
Interest rate	5.70%
Debt, carrying amount	$ 288	355
Freezer Installation Loan [Member]
Interest rate	6.30%
Debt, carrying amount	$ 1,143	1,334
Other Loans [Member]
Debt, carrying amount	$ 8	$ 9

Note 11 - Long-term Debt - Matu

Note 11 - Long-term Debt - Maturities of Loans Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
2022 (3 months remaining)	$ 679
2023	1,888
2024	5,544
2025	10,543
2026	5,222
Thereafter	2,596
Total debt, excluding unamortized debt issuance costs	26,472	$ 7,246
Less: unamortized debt issuance costs	(198)	(31)
Total debt	$ 26,274	$ 7,215

Note 12 - Warrants (Details Tex

Note 12 - Warrants (Details Textual) - $ / shares			9 Months Ended
	Mar. 25, 2021	May 14, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	May 31, 2016	Mar. 31, 2014
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0	$ 0	$ 0	$ 4.75
Class of Warrant or Right, Exercised During Period (in shares)			0	79,100
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								6,910,283
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 4.75
Warrants in Connection with WAVI Credit Facility [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							550,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 1.75
WAVI Holding AG and Taurus4757 GmbH Warrants [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)		2,747,970
Class of Warrant or Right, Exercised During Period (in shares)		3,871,405
Warrants Exercised [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)	70,030
Class of Warrant or Right, Exercised During Period (in shares)	79,100

Note 12 - Warrants - Summary of

Note 12 - Warrants - Summary of Warrant Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Beginning balance (in shares)	0	79,100
Beginning balance (in dollars per share)	$ 0	$ 4.75
Exercised, number of shares (in shares)	0	(79,100)
Exercised, weighted average exercise price (in dollars per share)	$ 0	$ 4.75
Ending balance (in shares)	0	0
Ending balance (in dollars per share)	$ 0	$ 0

Note 13 - Revenue (Details Text

Note 13 - Revenue (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Deferred Revenue, Revenue Recognized	$ 26,000	$ 482,000

Note 13 - Revenue - Revenues by

Note 13 - Revenue - Revenues by Product Line (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue	$ 40,747	$ 33,800	$ 117,500	$ 81,851
Product, Freezer and Thaw [Member]
Total revenue	15,326	17,610	49,331	40,021
Product, Cell Processing [Member]
Total revenue	18,082	11,505	48,336	30,131
Storage and Storage Services Product Revenue [Member]
Total revenue	260	86	560	293
Storage and Storage Services [Member]
Total revenue	4,312	2,250	11,099	6,417
Services, Cell Processing [Member]
Total revenue	18	0	18	0
Storage and Storage Services Rental Revenue [Member]
Total revenue	$ 2,749	$ 2,349	$ 8,156	$ 4,989

Note 13 - Revenue - Summary of

Note 13 - Revenue - Summary of Remaining Performance Obligations (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Rental Revenue [Member]
Service revenue, expected to be recognized in the future	$ 6,444
Service Revenue [Member]
Service revenue, expected to be recognized in the future	$ 270

Note 13 - Revenue - Summary o_2

Note 13 - Revenue - Summary of Remaining Performance Obligations 2 (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Rental Revenue [Member]
Service revenue, expected to be recognized in the future	$ 6,444
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Service revenue, expected to be recognized in the future	$ 1,809
Service revenue, expected to be recognized in the future, period (Year)	3 months
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Service revenue, expected to be recognized in the future	$ 3,735
Service revenue, expected to be recognized in the future, period (Year)	1 year
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Service revenue, expected to be recognized in the future	$ 900
Service revenue, expected to be recognized in the future, period (Year)	1 year
Service Revenue [Member]
Service revenue, expected to be recognized in the future	$ 270
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Service revenue, expected to be recognized in the future	$ 69
Service revenue, expected to be recognized in the future, period (Year)	3 months
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Service revenue, expected to be recognized in the future	$ 191
Service revenue, expected to be recognized in the future, period (Year)	1 year
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Service revenue, expected to be recognized in the future	$ 10
Service revenue, expected to be recognized in the future, period (Year)	1 year

Note 14 - Share-based Compens_3

Note 14 - Share-based Compensation (Details Textual) - USD ($)				3 Months Ended		9 Months Ended		21 Months Ended
	Feb. 24, 2022	Feb. 08, 2021	Mar. 25, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022
Share-Based Payment Arrangement, Expense				$ 6,299,000	$ 4,868,000	$ 17,671,000	$ 8,892,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense				0	6,000	0	21,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value				9,400,000		9,400,000		$ 9,400,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 60,000	1,400,000	$ 4,000,000	5,200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				0		0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)						3 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				$ 0		$ 0		0
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member]
Share-Based Payment Arrangement, Expense				0	0	0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 0	$ 9,700,000	$ 0	$ 19,500,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				0	0	0	0
Restricted Stock [Member]
Share-Based Payment Arrangement, Expense				$ 5,100,000	$ 4,400,000		$ 8,000,000	14,600,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				52,400,000		$ 52,400,000		$ 52,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value				23,300,000	31,100,000	32,100,000	35,700,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				3,100,000	5,100,000	$ 10,200,000	10,300,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						1,255,449
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)						448,056
Market-based Restricted Stock [Member]
Share-Based Payment Arrangement, Expense				1,200,000	413,000	$ 3,100,000	1,100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						349,568
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					4,500,000		4,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value	$ 6,700,000	$ 1,300,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year 2 months 12 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	218,280					218,280
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Historical Volatility Rate	63%	68%	78%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0%	0%	0%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.50%	0.10%	0.30%
Share Based Compensation Arrangement By Share Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Period (Year)	2 years	2 years	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value				0	0	$ 6,700,000	1,800,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested				$ 0	$ 0	$ 5,000,000	$ 10,200,000
Market-based Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	200%	200%	200%
Market-based Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	0%	0%
Market-based Restricted Stock [Member] | Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	240,428	30,616	109,140
Market-based Restricted Stock Second Issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value			$ 1,200,000

Note 14 - Share-based Compens_4

Note 14 - Share-based Compensation - Stock Option Activity (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares	9 Months Ended
	Sep. 30, 2022
Outstanding (in shares)	624,531
Outstanding, weighted average exercise price (in dollars per share)	$ 2.13
Exercised (in shares)	(158,075)
Exercised, weighted average exercise price (in dollars per share)	$ 1.94
Forfeited (in shares)	(10,000)
Forfeited, weighted average exercise price (in dollars per share)	$ 1.82
Outstanding as of September 30, 2022 (in shares)	456,456
Outstanding as of September 30, 2022 (in dollars per share)	$ 2.20
Stock options exercisable as of September 30, 2022 (in shares)	456,456
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.20

Note 14 - Share-based Compens_5

Note 14 - Share-based Compensation - Restricted Stock Activity (Details) - $ / shares		9 Months Ended
	Feb. 24, 2022	Sep. 30, 2022
Restricted Stock [Member]
Outstanding, shares (in shares)		1,212,783
Outstanding, weighted Average Exercise Price (in dollars per share)		$ 37.48
Granted (in shares)		1,255,449
Granted (in dollars per share)		$ 25.55
Vested (in shares)		(448,056)
Vested (in dollars per share)		$ 35.60
Forfeited (in shares)		(83,922)
Forfeited (in dollars per share)		$ 46.29
Outstanding, shares (in shares)		1,936,254
Outstanding, weighted Average Exercise Price (in dollars per share)		$ 29.79
Market-based Restricted Stock [Member]
Outstanding, shares (in shares)		139,756
Outstanding, weighted Average Exercise Price (in dollars per share)		$ 19.86
Granted (in dollars per share)		$ 21.26
Vested (in shares)	(218,280)	(218,280)
Vested (in dollars per share)		$ 10.95
Outstanding, shares (in shares)		271,044
Outstanding, weighted Average Exercise Price (in dollars per share)		$ 30.64
Granted (in shares)		349,568

Note 14 - Share-based Compens_6

Note 14 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock compensation expense	$ 6,299	$ 4,868	$ 17,671	$ 8,892
Cost of Sales [Member]
Stock compensation expense	809	742	2,619	1,047
General and Administrative Expense [Member]
Stock compensation expense	3,959	3,015	10,687	5,662
Selling and Marketing Expense [Member]
Stock compensation expense	829	560	2,272	1,012
Research and Development Expense [Member]
Stock compensation expense	$ 702	$ 551	$ 2,093	$ 1,171

Note 15 - Acquisitions (Details

Note 15 - Acquisitions (Details Textual) - USD ($)			3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 01, 2021	May 03, 2021	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total			$ 0		$ 6,451,000		$ 0	$ 6,451,000
Goodwill, Ending Balance			$ 224,741,000	$ 224,741,000			$ 224,741,000
Sexton Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	530,502
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims	10%
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total	$ 6,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables	509,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables	17,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period				198,000
Goodwill, Ending Balance	$ 28,470,000
Sexton Acquisition [Member] | Common Stock Issued to Acquire Participating Holders [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	477,452
Sexton Acquisition [Member] | Common Stock Deposited Into Escrow [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	53,050
GCI Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		6,636,470
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims		9%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables		$ 7,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables		53,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period				$ 607,000
Goodwill, Ending Balance		$ 137,822,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares, Before Adjustments (in shares)		6,646,870
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)		10,400
Business Combination, Escrow Shares, Period (Month)		24 months
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)						$ 58,900,000
Impairment of Intangible Assets, Finite-Lived						$ 11,000,000
GCI Acquisition [Member] | One GCI Stockholder [Member]
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)		10,400
Financing Receivable, after Allowance for Credit Loss, Total		$ 374,000

Note 15 - Acquisitions - Consid

Note 15 - Acquisitions - Consideration (Details) - USD ($) $ / shares in Units, $ in Thousands			9 Months Ended
	Sep. 01, 2021	May 03, 2021	Sep. 30, 2022	Sep. 30, 2021
BioLife stock price (in dollars per share)	$ 60.50	$ 35.07
Value of issued shares			$ 0	$ 264,718
BioLife shares outstanding (as of March 19, 2021) (in shares)		33,401,359
Sexton Acquisition [Member]
Merger consideration shares (in shares)	530,502
Value of issued shares	$ 32,095
Plus: Fair value of BioLife’s existing investment in Sexton	7,951
Less: Net working capital adjustment	(118)
Merger Consideration	$ 39,928
GCI Acquisition [Member]
Merger consideration shares (in shares)		6,636,470
Value of issued shares		$ 232,741
Merger Consideration		$ 234,909
Merger consideration percentage		19.90%
Merger consideration shares (in shares)		6,646,870
less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI (in shares)		10,400
plus: Settlement of BioLife prepaid deposits		$ 2,152
plus: Net settlement of BioLife accounts receivable		$ 16

Note 15 - Acquisitions - Fair V

Note 15 - Acquisitions - Fair Value of Net Assets Acquired (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 01, 2021	May 03, 2021
Goodwill	$ 224,741	$ 224,741
Sexton Acquisition [Member]
Cash			$ 1,516
Accounts receivable, net			492
Inventories			1,310
Prepaid expenses and other current assets			670
Property, plant and equipment, net			737
Operating lease right-of-use assets, net			470
Goodwill			28,470
Accounts payable			(291)
Lease liabilities, operating			(470)
Deferred tax liability			(1,482)
Other liabilities			(316)
Fair value of net assets acquired			39,928
Inventories			1,310
Sexton Acquisition [Member] | Developed Technology Rights [Member]
Developed technology			4,132
Sexton Acquisition [Member] | Customer Relationships [Member]
Developed technology			2,276
Sexton Acquisition [Member] | Trade Names [Member]
Developed technology			2,324
Sexton Acquisition [Member] | Noncompete Agreements [Member]
Developed technology			$ 90
GCI Acquisition [Member]
Cash				$ 43
Accounts receivable, net				7,076
Inventories				15,547
Prepaid expenses and other current assets				639
Property, plant and equipment, net				3,512
Operating lease right-of-use assets, net				1,741
Goodwill				137,822
Accounts payable				(9,837)
Lease liabilities, operating				(1,880)
Deferred tax liability				(24,133)
Other liabilities				(7,464)
Fair value of net assets acquired				234,909
Inventories				15,547
Financing lease right-of-use assets, net				114
Long-term deposits and other assets				4
Line of credit				(4,231)
Lease liabilities, financing				(114)
Long-term debt				(4,410)
GCI Acquisition [Member] | Indefinite In Process Research and Development [Member]
In-process research and development				67,440
GCI Acquisition [Member] | Developed Technology Rights [Member]
Developed technology				18,140
GCI Acquisition [Member] | Customer Relationships [Member]
Developed technology				7,020
GCI Acquisition [Member] | Trade Names [Member]
Developed technology				26,640
GCI Acquisition [Member] | Noncompete Agreements [Member]
Developed technology				$ 1,240

Note 15 - Acquisitions - Acquir

Note 15 - Acquisitions - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 01, 2021	May 03, 2021
Total identifiable intangible assets	$ 8,822
Sexton Acquisition [Member] | Developed Technology Rights [Member]
Developed technology	$ 4,132
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Minimum [Member]
Intangible assets, estimated useful life (Year)	5 years
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Maximum [Member]
Intangible assets, estimated useful life (Year)	9 years
Sexton Acquisition [Member] | Customer Relationships [Member]
Developed technology	$ 2,276
Intangible assets, estimated useful life (Year)	2 years
Sexton Acquisition [Member] | Trade Names [Member]
Developed technology	$ 2,324
Intangible assets, estimated useful life (Year)	11 years
Sexton Acquisition [Member] | Noncompete Agreements [Member]
Developed technology	$ 90
Intangible assets, estimated useful life (Year)	1 year
GCI Acquisition [Member]
Total identifiable intangible assets		$ 120,480
GCI Acquisition [Member] | Indefinite In Process Research and Development [Member]
In-process research and development		67,440
GCI Acquisition [Member] | Developed Technology Rights [Member]
Developed technology		$ 18,140
Intangible assets, estimated useful life (Year)		6 years
GCI Acquisition [Member] | Customer Relationships [Member]
Developed technology		$ 7,020
Intangible assets, estimated useful life (Year)		12 years
GCI Acquisition [Member] | Trade Names [Member]
Developed technology		$ 26,640
Intangible assets, estimated useful life (Year)		15 years
GCI Acquisition [Member] | Noncompete Agreements [Member]
Developed technology		$ 1,240
Intangible assets, estimated useful life (Year)		4 years

Note 15 - Acquisitions - Pro Fo

Note 15 - Acquisitions - Pro Forma Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Sexton Acquisition [Member]
Total revenue	$ 34,524	$ 85,189
Net income (loss)	(685)	4,612
GCI Acquisition [Member]
Total revenue	33,800	106,427
Net income (loss)	$ 79	$ (1,939)

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Expense (Benefit), Total	$ (599,000)	$ (4,988,000)	$ (4,937,000)	$ (17,540,000)
Effective Income Tax Rate Reconciliation, Percent, Total			5%
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount			$ 510,000
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount			$ 397,000
Effective Income Tax Rate Reconciliation, Before Discrete Items, Percent			5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%
Deferred Tax Assets, Valuation Allowance	$ 20,500,000		$ 20,500,000

Note 17 - Net (Loss) Income P_3

Note 17 - Net (Loss) Income Per Common Share - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net (loss) income	$ (9,957)	$ 79	$ (89,577)	$ 6,837
Amount attributable to unvested restricted shares	0	(2)	0	(212)
Amount attributable to warrants outstanding	0	0	0	(4)
Net (loss) income allocated to common shareholders	$ (9,957)	$ 77	$ (89,577)	$ 6,621
Basic (in shares)	42,647,967	40,911,801	42,376,392	37,435,224
Basic (in dollars per share)	$ (0.23)	$ 0	$ (2.11)	$ 0.18
Amount attributable to unvested restricted shares	$ 0	$ (2)	$ 0	$ (205)
Amount attributable to warrants	0	0	0	(4)
Diluted (loss) earnings per common share	$ (9,957)	$ 77	$ (89,577)	$ 6,628
Warrants (in shares)	0	0	0	24,338
Diluted weighted average shares issued and outstanding (in shares)	42,647,967	43,296,470	42,376,392	39,984,923
Diluted (in dollars per share)	$ (0.23)	$ 0	$ (2.11)	$ 0.17
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangements (in shares)	0	1,069,207	0	1,330,207
Restricted Stock [Member]
Share-Based Payment Arrangements (in shares)	0	1,315,462	0	1,195,154

Note 17 - Net (Loss) Income Com

Note 17 - Net (Loss) Income Common Share - Anti-dilutive Securities Excluded From Computation (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Anti-dilutive securities (in shares)	2,022,405	0	2,678,601	0
Share-based Payment Arrangement, Option and Restricted Stock Awards [Member]
Anti-dilutive securities (in shares)	2,022,405	0	2,678,601	0

Note 19 - Employee Benefit Pl_2

Note 19 - Employee Benefit Plan (Details Textual) - Defined Contribution Plan, 401 K [Member] - Pension Plan [Member] - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay		100%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 266,000		$ 237,000	$ 792,000	$ 587,000

Note 20 - Subsequent Events (De

Note 20 - Subsequent Events (Details Textual)	Oct. 01, 2022 USD ($) ft²	Sep. 30, 2022 USD ($)
Operating Lease, Liability, Total		$ 17,243,000
Subsequent Event [Member] | Lease in Woodinville, WA [Member]
Area of Real Estate Property (Square Foot) | ft²	13,578
Operating Lease, Liability, Total	$ 1,500,000
Monthly Base Rent Expense	$ 19,338